IPASS
2009
Iressa Pan-Asia Study
In 1,217 Asian, never/light-smoker patients with advanced lung adenocarcinoma, gefitinib improved progression-free survival in the EGFR-mutation-positive subgroup compared with carboplatin + paclitaxel.
Result
Efficacy: Progression-free survivalHR 0.74
Below 1 favours gefitinib, above 1 favours carboplatin + paclitaxel.
Also reported: EGFR-mutated: HR 0.48; EGFR wild-type: HR 2.85. Striking qualitative interaction.
- Subtopic
- EGFR-mutant NSCLC
- Design
- Open-label RCT
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Mok TS, et al. N Engl J Med. 2009;361(10):947-957.doi 10.1056/NEJMoa0810699
Discussion & critique
Foundational trial of precision oncology: mandated EGFR-mutation testing before first-line therapy in advanced NSCLC.